Neurocrine Biosciences, Inc

ACADIA Pharmaceuticals is a biopharmaceutical company utilizing technology to fuel drug discovery and clinical development of treatments for central nervous system disorders. It has five drug programs in clinical and pre-clinical development directed at large unmet medical needs and major commercial markets. ACADIA s three Phase II-stage clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, ACP-103 as an adjunctive therapy for schizophrenia and ACP-104 for treatment of schizophrenia. The company also has clinical and pre-clinical development programs in the areas of neuropathic pain and glaucoma in collaboration with Allergan. ACADIA maintains headquarters and biology research facilities in San Diego and a chemistry research facility in Malmo, Sweden. It trades on NASDAQ under the symbol ACAD.

Sta Pharmaceutical, with locations in Shanghai, Tianjin, Wuhan, Chengdu, and Changzhou, is a leading pharmaceutical company specializing in small molecule API process development, formulation development and manufacturing, as well as oligonucleotide and peptide discovery and development. With state-of-the-art R&D labs and a fully integrated R&D and manufacturing campus, Sta Pharmaceutical offers a comprehensive range of services from preclinical to commercial manufacturing, providing efficient and high-quality solutions to global pharma and biotech customers. With a focus on delivering innovative medicinal chemistry solutions, Sta Pharmaceutical utilizes its discovery chemistry platform to create, identify, and support the discovery of preclinical candidates. The company also offers custom synthesis solutions for various molecules, including amidite, GalNAc, unnatural amino acids, and other peptide-related building blocks, to accelerate therapeutic development. With its expertise and capabilities, Sta Pharmaceutical is committed to advancing the pharmaceutical industry and meeting the needs of its clients.Generated from the website

Prometheus Laboratories is a specialty pharmaceutical company committed to developing new ways to help physicians individualize patient care. Prometheus focuses on the treatment, diagnosis and detection of gastrointestinal, autoimmune and inflammatory diseases and disorders. The company s strategy includes the marketing and delivery of pharmaceutical products complemented by its proprietary, high-value diagnostic testing services. By integrating therapeutics and diagnostic services, Prometheus addresses the continuum of patient care, thereby providing physicians with a comprehensive solution to treat chronic diseases. The company s corporate offices are located in San Diego.